BR9911067A - Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal - Google Patents
Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renalInfo
- Publication number
- BR9911067A BR9911067A BR9911067-9A BR9911067A BR9911067A BR 9911067 A BR9911067 A BR 9911067A BR 9911067 A BR9911067 A BR 9911067A BR 9911067 A BR9911067 A BR 9911067A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- tgf
- kidney disease
- beta1
- treatment
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 208000017169 kidney disease Diseases 0.000 title abstract 4
- 108091006082 receptor inhibitors Proteins 0.000 title abstract 2
- 108010055795 Integrin alpha1beta1 Proteins 0.000 title 1
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 102000004266 Collagen Type IV Human genes 0.000 abstract 1
- 108010042086 Collagen Type IV Proteins 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 210000000585 glomerular basement membrane Anatomy 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Combustion & Propulsion (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Patente de Invenção: <B>"USO DE INIBIDORES DE RECEPTORES DE ALFA1BETA1 INTEGRINA E INIBIDORES TGF-BETA1 NO TRATAMENTO DE DOENçA RENAL"<D>. A presente invenção fornece métodos para tratar (isto é, atrasar o início de, retardar a progressão de, e/ou reverter) distúrbios renais (por exemplo, glomerulonefrite renal e/ou fibrose renal). Certos destes métodos envolvem administrar um inibidor de receptor de <244>1<225>1 integrina opcionalmente em combinação com um inibidor de TGF-<225> 1. A presente invenção também fornece um modelo de camundongo para doença renal onde o camundongo não expressa uma composição de colágeno tipo IV normal na GBM (isto é, não incorpora cadeias de colágeno <244>3(IV), <244>(IV), e <244>5(IV) em sua membrana basal glomerular) e não expressa o receptor de <244>1<225>1 integrina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8658798P | 1998-05-22 | 1998-05-22 | |
| US8876698A | 1998-06-02 | 1998-06-02 | |
| US15048598A | 1998-09-09 | 1998-09-09 | |
| PCT/US1999/011073 WO1999061040A2 (en) | 1998-05-22 | 1999-05-19 | USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9911067A true BR9911067A (pt) | 2001-02-06 |
Family
ID=56289911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9911067-9A BR9911067A (pt) | 1998-05-22 | 1999-05-19 | Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1079843B1 (pt) |
| JP (1) | JP2002516287A (pt) |
| CN (1) | CN1187084C (pt) |
| AT (1) | ATE359804T1 (pt) |
| BR (1) | BR9911067A (pt) |
| CA (1) | CA2329757C (pt) |
| CZ (1) | CZ296262B6 (pt) |
| DE (1) | DE69935853T2 (pt) |
| DK (1) | DK1079843T3 (pt) |
| EA (1) | EA004145B1 (pt) |
| EE (1) | EE04581B1 (pt) |
| ES (1) | ES2285841T3 (pt) |
| HU (1) | HUP0202048A3 (pt) |
| NO (1) | NO20005883L (pt) |
| NZ (1) | NZ508317A (pt) |
| PL (1) | PL345946A1 (pt) |
| PT (1) | PT1079843E (pt) |
| SG (1) | SG117434A1 (pt) |
| SI (1) | SI1079843T1 (pt) |
| TR (1) | TR200003432T2 (pt) |
| WO (1) | WO1999061040A2 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2529706T3 (es) | 1999-06-01 | 2015-02-24 | Biogen Idec Ma Inc. | Un anticuerpo monoclonal bloqueante contra el dominio alfa1-I de VLA-1, y su uso para el tratamiento de trastornos inflamatorios |
| US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| CA2384948C (en) * | 1999-09-14 | 2013-07-16 | Biogen, Inc. | Therapies for chronic renal failure using one or more integrin antagonists |
| IL151369A0 (en) * | 2000-03-09 | 2003-04-10 | Genzyme Corp | USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION |
| PL367324A1 (en) | 2001-04-13 | 2005-02-21 | Biogen, Inc. | Antibodies to vla-1 |
| EP1562632B1 (en) * | 2002-11-01 | 2012-12-05 | Boys Town National Research Hospital | Inducible ligand for alpha1 beta1 integrin and uses |
| US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
| CN105381459A (zh) | 2006-05-25 | 2016-03-09 | 比奥根Ma公司 | 治疗中风的方法 |
| GB0911888D0 (en) * | 2009-07-08 | 2009-08-19 | Oxford Biodynamics Ltd | Method of treating age related disorders |
| US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
| KR102118429B1 (ko) | 2012-04-25 | 2020-06-03 | 사노피 | 마이크로rna 화합물 및 mir-21 활성 조절 방법 |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| CN104450726A (zh) * | 2013-09-17 | 2015-03-25 | 深圳华大基因科技有限公司 | Col4a5基因突变体及其应用 |
| CN104212806B (zh) * | 2014-07-21 | 2017-05-17 | 深圳华大基因股份有限公司 | Alport综合征新的突变致病基因及其编码蛋白和应用 |
| US20230374141A1 (en) * | 2020-10-05 | 2023-11-23 | Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital | Combination therapy for alport renal disease |
| CN112575074B (zh) * | 2020-10-09 | 2022-12-27 | 中山大学 | Nestin基因及蛋白在治疗器官纤维化中的应用 |
| WO2023085396A1 (ja) * | 2021-11-12 | 2023-05-19 | Ｕｂｅ株式会社 | アルポート症候群を治療または予防するための医薬組成物 |
| CN114698592B (zh) * | 2022-04-29 | 2022-11-04 | 中国医学科学院北京协和医院 | 一种干燥综合征肾损害小鼠模型的构建方法及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9519667D0 (en) * | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
-
1999
- 1999-05-19 SI SI9930967T patent/SI1079843T1/sl unknown
- 1999-05-19 HU HU0202048A patent/HUP0202048A3/hu unknown
- 1999-05-19 EE EEP200000685A patent/EE04581B1/xx not_active IP Right Cessation
- 1999-05-19 CA CA2329757A patent/CA2329757C/en not_active Expired - Fee Related
- 1999-05-19 TR TR2000/03432T patent/TR200003432T2/xx unknown
- 1999-05-19 JP JP2000550500A patent/JP2002516287A/ja active Pending
- 1999-05-19 BR BR9911067-9A patent/BR9911067A/pt not_active IP Right Cessation
- 1999-05-19 PT PT99923224T patent/PT1079843E/pt unknown
- 1999-05-19 DE DE69935853T patent/DE69935853T2/de not_active Expired - Lifetime
- 1999-05-19 PL PL99345946A patent/PL345946A1/xx unknown
- 1999-05-19 DK DK99923224T patent/DK1079843T3/da active
- 1999-05-19 EP EP99923224A patent/EP1079843B1/en not_active Expired - Lifetime
- 1999-05-19 SG SG200300701A patent/SG117434A1/en unknown
- 1999-05-19 WO PCT/US1999/011073 patent/WO1999061040A2/en active IP Right Grant
- 1999-05-19 NZ NZ508317A patent/NZ508317A/en unknown
- 1999-05-19 AT AT99923224T patent/ATE359804T1/de not_active IP Right Cessation
- 1999-05-19 CN CNB998090247A patent/CN1187084C/zh not_active Expired - Fee Related
- 1999-05-19 EA EA200001092A patent/EA004145B1/ru not_active IP Right Cessation
- 1999-05-19 ES ES99923224T patent/ES2285841T3/es not_active Expired - Lifetime
- 1999-05-19 CZ CZ20004358A patent/CZ296262B6/cs not_active IP Right Cessation
-
2000
- 2000-11-21 NO NO20005883A patent/NO20005883L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA004145B1 (ru) | 2004-02-26 |
| CN1310625A (zh) | 2001-08-29 |
| EP1079843A2 (en) | 2001-03-07 |
| CZ296262B6 (cs) | 2006-02-15 |
| WO1999061040A3 (en) | 2000-01-27 |
| CA2329757A1 (en) | 1999-12-02 |
| JP2002516287A (ja) | 2002-06-04 |
| NO20005883D0 (no) | 2000-11-21 |
| TR200003432T2 (tr) | 2001-03-21 |
| CN1187084C (zh) | 2005-02-02 |
| DE69935853T2 (de) | 2008-01-10 |
| CA2329757C (en) | 2013-11-19 |
| WO1999061040A2 (en) | 1999-12-02 |
| NZ508317A (en) | 2004-01-30 |
| EE04581B1 (et) | 2006-02-15 |
| PT1079843E (pt) | 2007-06-26 |
| EP1079843B1 (en) | 2007-04-18 |
| PL345946A1 (en) | 2002-01-14 |
| ATE359804T1 (de) | 2007-05-15 |
| ES2285841T3 (es) | 2007-11-16 |
| EA200001092A1 (ru) | 2001-06-25 |
| DE69935853D1 (de) | 2007-05-31 |
| SI1079843T1 (sl) | 2007-10-31 |
| EE200000685A (et) | 2002-04-15 |
| NO20005883L (no) | 2001-01-17 |
| HUP0202048A3 (en) | 2006-11-28 |
| SG117434A1 (en) | 2005-12-29 |
| CZ20004358A3 (cs) | 2002-01-16 |
| WO1999061040A9 (en) | 2001-02-01 |
| HUP0202048A2 (en) | 2002-10-28 |
| DK1079843T3 (da) | 2007-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9911067A (pt) | Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal | |
| NO20072839L (no) | 4-hydroksybenzomorfaner | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| BRPI0710485B1 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
| EA200501601A1 (ru) | Соединения 1,2,4-оксадиазолбензойной кислоты и их применение | |
| BRPI0609711B8 (pt) | uso de uma solução aquosa com potencial redutivo oxidativo (orp) | |
| BRPI0409678A (pt) | métodos para identificar um composto, para tratar ou prevenir uma doença ou distúrbio em um humano, para incrementar a função de órgãos, tecidos, ou células excitáveis em um humano e para modular a atividade de um complexo de receptores de citocinas protetor de tecidos em um humano | |
| AP9901471A0 (en) | Sulfonamides and derivatives thereof that modulate the activity of endothelin. | |
| BR9708632A (pt) | Composto calcilìticos | |
| BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
| BR9809968A (pt) | Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional | |
| BR0013219A (pt) | Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| BR0312947A (pt) | terapias para insuficiência renal empregando-se interferon-beta | |
| BR9608835A (pt) | Processo para reduzir a hiperglicemia e estabilizar o nìvel de glicose no soro em humanos, tripicolinato crÈmico sintético em forma de dosagem unitária, e, uso do mesmo. | |
| PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
| BR0317616A (pt) | Aditivos resistentes à água para produtos de fibra de madeira e gesso | |
| BRPI0415896A (pt) | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia | |
| BR9909872A (pt) | uso de dexmedetomidina para uma unidade de sedação de proteção intensiva | |
| BR0108344A (pt) | Modulação de formação óssea | |
| BR0214798A (pt) | Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial | |
| BR9712307A (pt) | Pirazolinonas para o tratamento de potência enfraquecida | |
| BR9709370A (pt) | Gene semelhante a tolóide de mamìfero e proteìna. | |
| BR0102428A (pt) | Desproporcionalização de isopentano | |
| BR9908199A (pt) | Derivados de sulfonamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: O PRESENTE PEDIDO APRESENTA QUADRO REIVINDICATORIO COMPOSTO POR 36 REIVINDICACOES. NO ENTANTO, NO MOMENTO DO PEDIDO DE EXAME, FOI FEITA RETRIBUICAO RELATIVA A 9 REIVINDICACOES. PORTANTO, SOLICITA-SE QUE SEJA SANADA TAL IRREGULARIDADE PARA QUE SE DE PROSSEGUIMENTO AO EXAME TECNICO. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A E 12A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2135 DE 06/12/2011. |